- Conditions
- Bipolar Disorder
- Interventions
- Tamoxifen
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 1,351
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase 2 (CPT2) Deficiency, Mitochondrial Trifunctional Protein (TFP) Deficiency, Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency
- Interventions
- Triheptanoin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Pittsburgh, Pennsylvania
- Conditions
- Hemophilia A With Inhibitor, Haemophilia A Without Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor
- Interventions
- Not listed
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
- Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Multiple Myeloma
- Interventions
- Bortezomib, CC-5013
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Atlanta, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Lenalidomide
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 44
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 34 more
- Conditions
- Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- Best Practice, Ibrutinib
- Other · Drug
- Lead sponsor
- Jennifer Woyach
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorder, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Antineoplastic Agents, Analgesics, Non-Narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs
- Interventions
- CYNK-001
- Biological
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Denver, Colorado • St Louis, Missouri • Buffalo, New York + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia B
- Interventions
- nonacog beta pegol
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 13 Years to 70 Years · Male only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Jacksonville, Florida • Augusta, Georgia + 9 more
- Conditions
- Multiple Myeloma
- Interventions
- Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide, Cyclosporine, Doxorubicin hydrochloride, Etoposide, Fludarabine phosphate, Prednisone, Vincristine Sulfate, Methotrexate, GMCSF (granulocyte macrophage colony stimulating factor), GCSF (granulocyte colony stimulating factor)
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hemophilia A, Immune Tolerance
- Interventions
- FVIII, Emicizumab
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 0 Years to 12 Years · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Ovarian Cancer
- Interventions
- MOv-gamma chimeric receptor gene, aldesleukin, therapeutic allogeneic lymphocytes
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- COVID-19
- Interventions
- PF-06650833, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- amphotericin B deoxycholate, nystatin
- Drug
- Lead sponsor
- Aronex Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2007
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 47 more
- Conditions
- Depression
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hemophilia B
- Interventions
- PF-06838435 (formerly SPK-9001)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 17
- States / cities
- Sacramento, California • Metairie, Louisiana • New Orleans, Louisiana + 4 more
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Interventions
- BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
- Conditions
- Atrial Fibrillation (AF), Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Interventions
- Not listed
- Lead sponsor
- Tina Baykaner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Duarte, California • San Diego, California • Stanford, California
- Conditions
- Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
- Interventions
- 225Ac-ABD147
- Drug
- Lead sponsor
- Abdera Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Newport Beach, California • San Francisco, California • Santa Monica, California + 9 more
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy, Medical Chart Review, Teclistamab, Biospecimen Collection
- Biological · Procedure · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- NSCLC
- Interventions
- GI-4000
- Biological
- Lead sponsor
- GlobeImmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Transitional Cell Carcinoma
- Interventions
- TICE®-strain BCG, NY-ESO-1 protein, sargramostim
- Biological
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer
- Interventions
- RXC004, Nivolumab, Denosumab
- Drug · Biological
- Lead sponsor
- Redx Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Santa Rosa, California • Indianapolis, Indiana • Las Vegas, Nevada + 2 more